Evidence map›Paper›PMID 29702654›Full record

ArticlePLoS neglected tropical diseases2018

Identification and characterization of the Fasciola hepatica sodium- and chloride-dependent taurine transporter.

Bulut Hamali, Sandra Pichler, Elisabeth Wischnitzki, Klaus Schicker, Melanie Burger, Marion Holy, Kathrin Jaentsch, Martina Molin, Eva Maria Sehr, Oliver Kudlacek and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity.Liver international : official journal of the International Association for the Study of the Liver · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bulut HamaliInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Sandra PichlerInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Elisabeth WischnitzkiCenter for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Tulln, Austria.
Klaus SchickerInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Melanie BurgerInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Marion HolyInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Kathrin JaentschInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Martina MolinInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Eva Maria SehrCenter for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Tulln, Austria.
Oliver KudlacekInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.ORCID 0000-0002-3086-8551
Michael FreissmuthInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria and Gaston H. Glock Research Laboratories for Exploratory Drug Development, Vienna, Austria.
Medical University of Vienna · ATAustrian Institute of Technology · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The parasitic liver fluke Fasciola hepatica infests mainly ruminants, but it can also cause fasciolosis in people, who ingest the metacercariae encysted on plants. The drug of choice to treat fasciolosis is triclabendazole (TBZ), which has been on the market for several decades. This is also true for the other available drugs. Accordingly, drug-resistant flukes have been emerging at an increasing rate making it desirable to identify alternative drug targets. Here, we focused on the fact that adult F. hepatica persists in the hostile environment of the bile ducts of infected organisms. A common way to render bile acids less toxic is to conjugate them to taurine (2-aminoethanesulfonic acid). We cloned a transporter from the solute carrier-6 (SLC6) family, which was most closely related to the GABA-transporter-2 of other organisms. When heterologously expressed, this F. hepatica transporter supported the high-affinity cellular uptake of taurine (KM = 12.0 ± 0.5 μM) but not of GABA. Substrate uptake was dependent on Na+- and Cl- (calculated stoichiometry 2:1). Consistent with the low chloride concentration in mammalian bile, the F. hepatica transporter had a higher apparent affinity for Cl- (EC50 = 14±3 mM) than the human taurine transporter (EC50 = 55±7 mM). We incubated flukes with unconjugated bile acids in the presence and absence of taurine: taurine promoted survival of flukes; the taurine transporter inhibitor guanidinoethansulfonic acid abolished this protective effect of taurine. Based on these observations, we conclude that the taurine transporter is critical for the survival of liver flukes in the bile. Thus, the taurine transporter represents a candidate drug target.

Indexed as

Amino Acid SequenceAnimalsAnthelminticsBenzimidazolesBile Acids and SaltsCell Line, TumorChloridesFasciola hepaticaFascioliasisGene ExpressionGenes, ReporterHelminth ProteinsHumansMembrane GlycoproteinsMembrane Transport ProteinsPhylogenyAnthelminticsBenzimidazolesBile Acids and SaltsChloridesHelminth ProteinsMembrane GlycoproteinsMembrane Transport ProteinsSodiumTaurine TransportersTriclabendazole

Identifiers

PMID29702654
PMCPMC5942844
OpenAlexW2800750217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.